Phytoestrogens과 골대사
Phytoestrogens and Bone Metabolism
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Although most gynecologists had prescribed estrogen with or without progestin for their menopausal patients before the publication of Women’s health Initiative (WHI) trial findings, only 35 to 40% of women ever started hormone therapy (HT) and many discontinued it, because of perceived side effects and discomfort. HT will not likely to be regularly prescribed in the future given the recommendations by several groups against long-term use for chronic diseases after the release of the findings of the WHI. Consequently, many postmenopausal women have turned to botanical dietary supplements containing phytoestrogen as an alternative to HT. Although there are numerous studies in the literature over the last decade trying to address the efficacy of phytoestrogens on bone health in animal models and in humans, the efficacy of phytoestrogens as bone-protective agents in vivo remains unclear. Differences in the bioactivities of individual phytoestrogens, differences in bioavailability and metabolism of phytoestrogens within different study populations, and imprecise reporting of the form and dose of phytoestrogens provided in intervention studies may have leaded to the disparity in study results. However, the preventive effect of phytoestrogens for bone loss is promising. This review discusses the effects of phytoestrogens on bone metabolism and their roles on the prevention and treatment of postmenopausal osteoporosis.
Abstract
Although most gynecologists had prescribed estrogen with or without progestin for their menopausal patients before the publication of Women’s health Initiative (WHI) trial findings, only 35 to 40% of women ever started hormone therapy (HT) and many discontinued it, because of perceived side effects and discomfort. HT will not likely to be regularly prescribed in the future given the recommendations by several groups against long-term use for chronic diseases after the release of the findings of the WHI. Consequently, many postmenopausal women have turned to botanical dietary supplements containing phytoestrogen as an alternative to HT. Although there are numerous studies in the literature over the last decade trying to address the efficacy of phytoestrogens on bone health in animal models and in humans, the efficacy of phytoestrogens as bone-protective agents in vivo remains unclear. Differences in the bioactivities of individual phytoestrogens, differences in bioavailability and metabolism of phytoestrogens within different study populations, and imprecise reporting of the form and dose of phytoestrogens provided in intervention studies may have leaded to the disparity in study results. However, the preventive effect of phytoestrogens for bone loss is promising. This review discusses the effects of phytoestrogens on bone metabolism and their roles on the prevention and treatment of postmenopausal osteoporosis.
참고문헌 (55)
- Lagari VS, "Phytoestrogens and bone health", Curr Opin Endocrinol Diabetes Obes, 17, pp.546~553 (2010)
- Chiang SS, "Benificial effects of phytoestrogens and their metabolites produced by intestinal microflora on bone health", Appl Microbiol Biotechnol, 97, pp.1489~1500 (2013)
- Kuiper G, "Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors α and β", Endocrinology, 138, pp.863~870 (1997)
- Lee Y, "Physiological concentrations of genistein stimulate the proliferation and protect against free radical-induced oxidative damage of MC3T3-E1 osteoblast-like cells", Nutr Res, 21, pp.1287~1293 (2001)
- Pan W, "Genistein stimulates the osteoblastic differentiation via NO", cGMP in bone marrowculture, 2005, pp.94, 307~316
- Federici E, "Soybean extract and its isoflavones, genistein and daidzein, stimulate BMP-2 expression and bone formation by inhibiting the mevalonate pathway in osteoblast cells", Bone, 34(Suppl), pp.S4~S4 (2004)
- Dang ZC, "Peroxisome proliferator-activated receptor gamma (PPAR gamma) as a molecular target for the soy phytoestrogen genistein", J Biol Chem, 278, pp.962~967 (2003)
- Dang ZC, "The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis", J Bone Miner Res, 19, pp.853~861 (2004)
- Chen X, "Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation", J Nutr Biochem, 14, pp.342~349 (2003)
- Wu XT, "Coumestrol promotes proliferation and osteoblastic differentiation in rat bone marrow stromal cells", J Biomed Mater Res B Appl Biomater, 90, pp.621~628 (2009)
- Alcantara EH, "Diosgenin stimulates osteogenic activity by increasing bone matrix protein synthesis and bonespecific transcription factor Runx2 in osteoblastic MC3T3-E1 cells", J Nutr Biochem, 22, pp.1055~1063 (2011)
- Seidlova-Wuttke D, "Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta", Eur J Endocrinol, 149, pp.351~362 (2003)
- Yamaguchi M, "Effect of polyphenols on calcium content and alkaline phosphatase activity in rat femoral tissues in vitro", Biol Pharm Bull, 24, pp.1437~1439 (2001)
- Fuller K, "TRANCE is necessary and sufficient for osteoblastmediated activation of bone resorption in osteoclasts", J Exp Med, 188, pp.997~1001 (1998)
- Theoleyre S, "The molecular triad OPG", RANK, Cytokine Growth Factor Rev, pp.2004, 15[DOI]
- Rassi CM, "Down-regulation of osteoclast differentiation by daidzein via caspase 3", J Bone Miner Res, 17, pp.630~638 (2002)
- Huang YF, "Decreased circulating levels of tumor necrosis factor-alpha in postmenopausal women during consumption of soy-containing isoflavones", J Clin Endocr Metab, 90, pp.3956~3962 (2005)
- Li BB, "Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation", Biol Pharm Bull, 26, pp.780~786 (2003)
- Chen XW, "Effects of genistein on expression cell of bone markers during MC3T3-E1 osteoblastic differentiation", J Nutr Biochem, 14, pp.342~349 (2003)
- Chen XW, "Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogenreceptordependent pathway", Biochem Biophys Res Comm, 295, pp.417~422 (2002)
- Suh KS, "Soybean isoflavones inhibit tumor necrosis factor-alpha-induced apoptosis and the production of interleukin-6 and prostaglandin E-2 in osteoblastic cells", Phytochemistry, 63, pp.209~215 (2003)
- Okamoto F, "Genistein, a soybean isoflavone, inhibits inward rectifier K+ channels in rat osteoclasts (Abstract)", Jap J Physiol, 51, pp.501~509 (2001)
- Cotter AA, "The effect of oestrogen and dietary phyto-oestrogens on transepithelial calcium transport in human intestinal-like Caco-2 cells", Br J Nutr, 89, pp.755~765 (2003)
- Arjmandi BH, "Soy protein: its effects on intestinal calcium transport, serum vitamin D, and insulinlike growth factor-I in ovariectomized rats", Calcif Tissue Int, 70, pp.483~487 (2002)
- Spence LA, "The effect of soy protein and soy isoflavones on calcium metabolism in postmenopausal women: a randomized crossover study", Am J Clin Nutr, 81, pp.916~922 (2005)
- Fanti P, "The phytoestrogen genistein reduces bone loss in short-term ovariectomised rats", Osteoporosis Int, 8, pp.274~281 (1998)
- Nakai M, "Dietary soy protein and isoflavones: no effect on the reproductive tract and minimal positive effect on bone resorption in the intact female Fischer 344 rat", Food Chem Toxicol, 43, pp.945~949 (2005)
- James P, "Influence of dietary protein and phyto-oestrogens on bone mineralization in the young rat", Nutr Res, 22, pp.385~392 (2002)
- Hotchkiss CE, "Multigenerational exposure to genistein does not increase bone mineral density in rats", Bone, 37, pp.720~727 (2005)
- Arjmandi BH, "Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats", Am J Clin Nutr, 68(6 Suppl), pp.1358S~1363S (1998)
- Picherit C, "Dose-dependent bone-sparing effects of dietary isoflavones in the ovariectomised rat", Br J Nutr, 85, pp.307~316 (2001)
- Picherit C, "Soybean isoflavones dose-dependently reduce bone turnover but do not reverse established osteopenia in adult ovariectomised rats", J Nutr, 131, pp.723~728 (2001)
- Dae Won Kim, "Soy Isoflavones Mitigate Long-Term Femoral and Lumbar Vertebral Bone Loss in Middle-Aged Ovariectomized Mice", Journal of Medicinal Food, 12(3), pp.536~541 (2009), 한국식품영양과학회
- Chiang SS, "Antiosteoporotic effects of Lactobacillus fermented soy skim milk on bone mineral density and the microstructure of femoral bone in ovariectomized mice", J Agric Food Chem, 59, pp.7734~7742 (2011)
- Chiang SS, "Effect of bioactive compounds in lactobacilli-fermented soy skim milk on femoral bone microstructure of aging mice", J Sci Food Agric, 92, pp.328~335 (2012)
- Uesugi T, "Comparative study on reduction of bone loss and lipid metabolism, abnormality in ovariectomized rat by soy isoflavone, daidzein, genistein, and glycytin", Biol Pharm Bull, 24, pp.368~372 (2001)
- Mei J, "High Dietary Phytoestrogen Intake Is Associated with Higher Bone Mineral Density in Postmenopausal but Not Premenopausal Women", J Clin Endocrinol Metab, 86, pp.5217~5221 (2001)
- Kim MK, "Relationships of urinary phytooestrogen excretion to BMD in postmenopausal women", Clin Endocrinol, 56, pp.321~328 (2002)
- Horiuchi T, "Effect of Soy Protein on Bone Metabolism in Postmenopausal Japanese Women", Osteoporosis Int, 11, pp.721~724 (2000)
- Song KB, "Prevalence of daidzein- metabolizing phenotypes differs between Caucasian and Korean American women and girls", J Nutr, 136, pp.1347~1351 (2006)
- Greendale G, "Dietary Soy Isoflavones and Bone Mineral Density: Results from the Study of Women's Health Across the Nation", Am J Epidemiol, 155, pp.746~751 (2002)
- Kritz-Silverstein, "Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women", J Womens Health Gend based Med, 11, pp.69~78 (2002)
- Potter S, "Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women", Am J Clin Nutr, 68, pp.1375S~1379S (1998)
- Atkinson C, "The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial", Am J Clin Nutr, 79, pp.326~333 (2004)
- Harkness L, "Decreased bone resorption with soy isoflavone supplementation in postmenopausal women", J Womens Health, 13, pp.1000~1007 (2004)
- Brink E, "PHYTOS Investigators. Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study", Am J Clin Nutr, 87, pp.761~770 (2008)
- Frankenfeld CL, "Familial correlations, segregation analysis and nongenetic correlates of soy isoflavone-metabolising phenotypes", Exp Biol Med, 229, pp.902~913 (2004)
- Ibarreta D, "Possible health impact of phytoestrogens and xenoestrogens in food", APMIS, 109, pp.161~184 (2001)
- Nettleton JA, "Plasma phytoestrogens are not altered by probiotic consumption in postmenopausal women with and without a history of breast cancer", J Nutr, 134, pp.1998~2003 (2004)
- Wangen KE, "Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women", J Clin Endocr Metab, 85, pp.3043~3048 (2000)
- Koyama I, "Effects of natto (fermented soybean; made from isoflavone- rich soybean) supplemented with zinc and calcium on bone density and bone metabolic markers of postmenopausal women", J Nutr, 134(Suppl), pp.S1288~S1289 (2004)
- Wuttke W, "The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers", Maturitas, 44, pp.S67~S77 (2003)
- Morabito N, "Effect of genistein and Hormone replacement therapy on bone loss in early postmenopausal women: A randomized doubleblind placebo-controlled study", J Bone Miner Res, 17, pp.1904~1912 (2002)
- Lydeking-Olsen E, "Isoflavone- Rich Soymilk Prevents Bone Loss in the Lumbar Spine of Postmenopausal Women: A Two-Year Study", J Nutr, 132, pp.582S~ (2002)
- Alexandersen P, "Ipriflavone in the Treatment of Postmenopausal Osteoporosis: A Randomized Controlled Trial for the Ipriflavone Multicenter European Fracture Study", JAMA, 285, pp.1482~1488 (2001)